Arsenic trioxide (Trisenox®) in patients with relapsed or refractory multiple myeloma (MM):: Final report of a phase II clinical study.

被引：0
|
作者：
Hussein, MA
Mason, J
Saleh, MN
Rifkin, RM
Ravandi, F
机构：
[1] Cleveland Clin Canc Ctr, Multiple Myeloma Res Program, Cleveland, OH USA
[2] Scripps Clin, San Diego, CA USA
[3] Georgia Canc Specialists, Atlanta, GA USA
[4] Rocky Mt Canc Ctr, Denver, CO USA
[5] Univ Illinois, Chicago, IL USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5138
引用
收藏
页码：393B / 393B
页数：1
相关论文
共 50 条
  • [21] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Kaplita, S.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    BLOOD, 2012, 120 (21)
  • [23] Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma
    Kraut, EH
    Young, D
    Farag, S
    James, AG
    Solove, RJ
    LEUKEMIA RESEARCH, 2005, 29 (10) : 1233 - 1234
  • [24] Trisenox® (arsenic trioxide) in patients with Myelodysplastic syndromes (MDS):: Preliminary results of a phase 1/2 study.
    Vey, N
    Dreyfus, F
    Guerci, A
    Fenaux, P
    Dombret, H
    Burnett, A
    Bosly, A
    Feremans, W
    Bowen, D
    Garzon, F
    BLOOD, 2003, 102 (11) : 422A - 423A
  • [25] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Harvey, Colleen K.
    Colson, Kathleen
    Mitchell, Monica
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1264 - 1264
  • [27] A phase I/II multicenter, safety and efficacy study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) in patients with relapsed or refractory multiple myeloma
    Berenson, JR
    BLOOD, 2004, 104 (11) : 659A - 659A
  • [28] The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review
    Roellig, Christoph
    Illmer, Thomas
    CANCER TREATMENT REVIEWS, 2009, 35 (05) : 425 - 430
  • [29] Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.
    Richardson, Paul
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur
    Alsina, Melissa
    Ghobrial, Irene
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Colson, Kathleen
    McKenney, Mary L.
    Lunde, Laura
    Kennedy, Sarah
    Kosakowski, Kara
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert D.
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 614 - 615
  • [30] The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma
    Li, Xin
    Sun, Wan-Jun
    ONCOTARGETS AND THERAPY, 2015, 8 : 775 - 781
12345